Liquiritin targets NF-κB/MAPK signaling to attenuate osteoclastogenesis and triggers apoptosis through PPARγ activation
Phytomedicine · 2025
DOI: 10.1016/j.phymed.2025.157604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Jingtao Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang 313000, China; Huzhou Central Hospital, Fifth School of C…. Hauptthemen laut MEDLINE: Glucosides, PPAR gamma, Flavanones, Apoptosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Zhejiang Province Public Welfare Technology Application Research Project.
Abstract (Originalsprache)
BACKGROUND: Postmenopausal Osteoporosis (PMOP) is an estrogen-deficiency disorder that leads to impaired bone remodeling and a higher incidence of fractures. Liquiritin, a flavonoid from Glycyrrhiza uralensis, has documented bioactivities but previously unexplored potential for PMOP treatment. PURPOSE: To investigate liquiritin's therapeutic effects on PMOP and its underlying mechanisms, constituting the first comprehensive investigation of its role in osteoclasts regulation and apoptosis induction within PMOP pathophysiology. METHODS: Network pharmacology was employed to predict potential targets of Liquiritin in PMOP. The CCK-8 assay assessed its effect on bone marrow-derived macrophages (BMDMs) viability. RANKL was used to induce BMDMs differentiation into mature osteoclasts. TRAcP and F-actin staining detected osteoclasts formation; bone resorption assays evaluated functionality. Western blotting and immunofluorescence were applied to evaluate osteoclasts-related proteins, MAPK/NF-κB pathway activity, and apoptosis. Notably, molecular docking predicted Liquiritin's binding to PPARγ, validated by CETSA. An OVX-induced PMOP mouse model was constructed in vivo; bone microarchitecture and osteoclasts activity were evaluated using micro-CT, H&E, and TRAcP staining. RESULTS: Liquiritin suppressed osteoclasts formation and bone resorption in vitroand mitigated bone loss in vivo by downregulating osteoclasts-specific genes, inhibiting MAPK/NF-κB pathways, and most importantly, inducing PPARγ-mediated apoptosis-a novel mechanistic insight not previously reported. CONCLUSION: Liquiritin exerts anti-osteoporotic effects by targeting Osteoclastogenesis, inducing apoptosis, and inhibiting bone resorption via PPARγ activation, highlighting its novel therapeutic potential for PMOP treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang 313000, China; Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zheji…
Förderung
- Zhejiang Province Public Welfare Technology Application Research Project
Zitieren
APA
Wu, J., Zhang, Y., Wang, Y., Liu, H., Sheng, X., Li, X., Lu, Q., & Wang, Y. (2025). Liquiritin targets NF-κB/MAPK signaling to attenuate osteoclastogenesis and triggers apoptosis through PPARγ activation. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157604
Vancouver
Wu J, Zhang Y, Wang Y, Liu H, Sheng X, Li X, et al. Liquiritin targets NF-κB/MAPK signaling to attenuate osteoclastogenesis and triggers apoptosis through PPARγ activation. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.157604
BibTeX
@article{Wu2025,
author = {Wu, Jingtao and Zhang, Yuhao and Wang, Yipeng and Liu, Huabin and Sheng, Xiao and Li, Xiongfeng and Lu, Qian and Wang, Yongli},
title = {Liquiritin targets NF-κB/MAPK signaling to attenuate osteoclastogenesis and triggers apoptosis through PPARγ activation},
journal = {Phytomedicine},
year = {2025},
doi = {10.1016/j.phymed.2025.157604}
}
EUVIMED